Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 94
- Registration Number
- NCT00398489
- Locations
- 🇩🇪
Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
🇩🇪Klinikum Deggendorf, Deggendorf, Germany
🇩🇪Universitaetsfrauenklinik - Koeln, Cologne, Germany
Testosterone Effects on Men With the Metabolic Syndrome
- Conditions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2008-12-05
- Target Recruit Count
- 72
- Registration Number
- NCT00382057
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT00357110
- Locations
- 🇳🇴
Research SIte, Porsgrunn, Norway
🇳🇴Research Site, Trondheim, Norway
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2013-06-24
- Target Recruit Count
- 11
- Registration Number
- NCT00354640
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Faslodex Advanced Breast Cancer Local Chinese Study
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT00327769
- Locations
- 🇨🇳
Research Site, Xi AN, China
Arthralgia During Anastrozole Therapy for Breast Cancer
- Conditions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 114
- Registration Number
- NCT00323479
- Locations
- 🇫🇷
Research Site, Poitiers, France
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10273
- Registration Number
- NCT00310180
- Locations
- 🇺🇸
Saint Ann's Hospital, Westerville, Ohio, United States
🇨🇦McGill University Department of Oncology, Montreal, Quebec, Canada
🇨🇦CHUM-Hotel Dieu de Montreal, Montreal, Quebec, Canada
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 1914
- Registration Number
- NCT00301457
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
- Conditions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 856
- Registration Number
- NCT00300508
- Locations
- 🇦🇹
Research site, Hollabrunn, Austria
🇦🇹Research Site, Zams, Austria
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 1803
- Registration Number
- NCT00295646
- Locations
- 🇦🇹
State Hospital Klagenfurt, Surgery, Klagenfurt, Carinthia, Austria
🇦🇹State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria
🇩🇪Medical University Kiel, Kiel, Schleswig-Holstein, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.